Capricor Says Cash Funds At Least 12 Months While It Prepares For Deramiocel Launch
Launch and manufacturing preparations pushed quarterly expenses to approximately $44.7 million, even with a roughly 10% workforce cut.
Capricor Therapeutics, which is seeking approval for Deramiocel to slow loss of arm and hand function in Duchenne muscular dystrophy, said its resources should cover at least 12 months of operations in Tuesday’s SEC earnings filing. That outlook excludes potential product sales, while the company prepares for a launch dependent on FDA approval.
Launch Spending Outpaces Staff Cuts
Capricor held approximately $198.5 million in cash, cash equivalents, restricted cash and marketable securities at September 30, against approximately $318.1 million at December 31, 2025. The company said it sold no shares through its market-based share-sale program from January 1 through Tuesday.
Third-quarter operating expenses rose to approximately $44.7 million from $26.3 million a year earlier. Capricor attributed the increase mainly to preparations for commercialization and expanded manufacturing, even as it cut approximately 10% of employees during the quarter to reduce costs and focus resources.
Research and development spending reached $29.6 million, versus $20.4 million a year earlier; general and administrative costs reached $15.1 million, versus $5.9 million. For the first nine months, operating expenses totaled approximately $124.4 million, against $79.0 million.
The quarterly net loss widened to approximately $42.7 million, or $0.73 per share, from $24.6 million, or $0.54 per share. Nine-month losses reached approximately $117.3 million, or $2.03 per share, versus $74.9 million, or $1.64 per share. Capricor recognized no revenue in the first nine months of either year.
Its funding outlook also excludes proceeds from selling a priority review voucher, if one is received, and other non-operating capital. Management expects to offer a longer-term outlook once the regulatory position is clearer.
A Narrower Case For FDA Approval
The FDA rejected the initial application in July 2025, citing insufficient evidence of effectiveness for cardiomyopathy. An advisory committee subsequently voted 9–3 against the evidence for that heart condition.
Capricor’s August submission proposed an indication for upper-limb impairment in patients older than 9, adding extension-study data and analyses. The FDA treated it as a major amendment and extended the review to November 22, 2026.
In October, Capricor presented results showing 76% slower deterioration in arm and hand function among patients who switched from placebo to Deramiocel. They lost 1.56 fewer points on the arm-and-hand assessment than during their placebo year. This was an open-label comparison across treatment periods, rather than a concurrent placebo comparison.
The original late-stage trial results, published in The Lancet in July, showed statistically significant slowing of upper-limb progression. Jonathan Soslow of Vanderbilt University Medical Center presented slower heart-muscle scarring versus placebo Saturday, findings that earned the American Heart Association’s Outstanding Research Award in Pediatric Cardiology.
Separately, a July 2026 FDA clinical-trial inspection produced one observation. Capricor submitted a response and awaits feedback.
Deramiocel Takes Priority Over Other Programs
Capricor has no commercially approved products. It develops cell therapies and treatments using exosomes—tiny particles released by cells—and operates Deramiocel manufacturing facilities in San Diego and Los Angeles.
Its San Diego facility is positioned to supply an initial launch, if approved. “With our San Diego facility operational, we are prepared to move quickly to bring Deramiocel to patients, if approved,” said Linda Marbán, Capricor’s chief executive officer. The company targets validation of an expanded cleanroom in the first half of 2027.
Capricor has slowed work outside Deramiocel, including its exosome platform. It has begun regulatory engagement in Europe and Japan; expansion into younger Duchenne patients and Becker muscular dystrophy depends on the U.S. regulatory outcome.
The company also continues a distribution-contract dispute with Nippon Shinyaku and its U.S. subsidiary, NS Pharma. Capricor previously withdrew its preliminary-injunction request without prejudice to pursue arbitration following the FDA decision, and expects the hearing to begin in mid-2027.
The FDA’s target decision date remains November 22, 2026; Deramiocel has not been approved for commercial use.
Sources
- 8-K Filing — CAPRICOR THERAPEUTICS, INC. (CAPR) — SEC EDGAR
- Exhibit capr-ex99d1.htm — CAPRICOR THERAPEUTICS, INC. 8-K exhibit — SEC EDGAR
- FDA's rare disease framework faces its first real test in Capricor’s DMD drug - BioSpace — biospace.com
- CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision — Yahoo Finance
- Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November - BioSpace — biospace.com
- Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology — Yahoo Finance
- Capricor Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- 8-K filed 2026-08-24 — CAPRICOR THERAPEUTICS, INC. (earlier disclosure) — SEC EDGAR